Vida Veronica Ruíz Herrera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vida Veronica Ruíz Herrera has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Luz Alicia González-Hernández
Unidad de VIH, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara 44350, Mexico
4 shared publications - Pedro Martínez-Ayala
HIV Unit, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara 44280, Mexico
4 shared publications - Adriana Valle Rodríguez
HIV Unit, Civil Hospital of Guadalajara "Fray Antonio Alcalde", Guadalajara, Jalisco, Mexico
3 shared publications - Jaime Federico Andrade Villanueva
Unidad de VIH, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara 44350, Mexico
3 shared publications - Luis Eduardo Del Moral Trinidad
Doctorado en Ciencias de la Salud Pública, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44430, Mexico
3 shared publications - José Adán Vizcaíno Résendiz
Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Unidad de VIH, Guadalajara CP 44200, Jalisco, Mexico
2 shared publications
Latest Publications
- Open Access
- 24 January 2026
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 23 (1)
Multifactorial determinants of lost to follow-up in antiretroviral therapy: evidence from a case–control study in Mexico
Loss to follow-up (LTFU) remains a major challenge in achieving sustained HIV care. Understanding individual and structural factors influencing disengagement is essential to improve retention, particularly in low- and middle-income settings. This study aimed to identify predictors of LTFU among adults receiving antiretroviral therapy (ART) in western Mexico. A case-control study was conducted among adults with HIV treated at a tertiary hospital. Cases met the national definition of LTFU (≥ 90 days beyond the expected clinic visit or pharmacy refill), while controls were retained patients during the same period. A total of 919 participants were included (148 LTFU, 771 retained). Multivariable logistic regression identified factors associated with LTFU. Median age was 42 years (IQR 34, 51) and 88% were male. The multivariable analysis identified that age was associated with lower risk of LTFU (adjusted odds ratio [aOR] per year, 0.94; 95% CI, 0.91-0.96). Secondary ART resistance (aOR, 4.03; 95% CI, 1.59-9.99), hard-drug use (aOR, 2.57; 95% CI, 1.68-3.93), psychiatric disorders (aOR, 3.58; 95% CI, 2.23-5.72), lower educational level (≥ upper secondary vs. no formal education/primary: aOR, 2.30; 95% CI, 1.34-3.94), emergency department visits (aOR, 2.63; 95% CI, 1.72-4.04), and years living with HIV (aOR per year, 1.06; 95% CI, 1.02-1.10) were associated with higher odds of LTFU. These findings highlight the role of psychosocial and structural determinants of LTFU, underscoring the need for integrated interventions addressing education, mental health, and substance use to improve retention in HIV care in Mexico.
- 24 January 2026
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 23 (1)
Open AccessMultifactorial determinants of lost to follow-up in antiretroviral therapy: evidence from a case–control study in Mexico
Loss to follow-up (LTFU) remains a major challenge in achieving sustained HIV care. Understanding individual and structural factors influencing disengagement is essential to improve retention, particularly in low- and middle-income settings. This study aimed to identify predictors of LTFU among adults receiving antiretroviral therapy (ART) in western Mexico. A case-control study was conducted among adults with HIV treated at a tertiary hospital. Cases met the national definition of LTFU (≥ 90 days beyond the expected clinic visit or pharmacy refill), while controls were retained patients during the same period. A total of 919 participants were included (148 LTFU, 771 retained). Multivariable logistic regression identified factors associated with LTFU. Median age was 42 years (IQR 34, 51) and 88% were male. The multivariable analysis identified that age was associated with lower risk of LTFU (adjusted odds ratio [aOR] per year, 0.94; 95% CI, 0.91-0.96). Secondary ART resistance (aOR, 4.03; 95% CI, 1.59-9.99), hard-drug use (aOR, 2.57; 95% CI, 1.68-3.93), psychiatric disorders (aOR, 3.58; 95% CI, 2.23-5.72), lower educational level (≥ upper secondary vs. no formal education/primary: aOR, 2.30; 95% CI, 1.34-3.94), emergency department visits (aOR, 2.63; 95% CI, 1.72-4.04), and years living with HIV (aOR per year, 1.06; 95% CI, 1.02-1.10) were associated with higher odds of LTFU. These findings highlight the role of psychosocial and structural determinants of LTFU, underscoring the need for integrated interventions addressing education, mental health, and substance use to improve retention in HIV care in Mexico.
- Open Access
- 7 January 2025
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 14 (1) , e59562
Simplified Medication Adherence Questionnaire (SMAQ) for People Living With HIV in a National Hospital in Mexico: Instrument Validation Study
Background: Adherence to antiretroviral therapy is a critical component in achieving viral suppression in people living with HIV in addition to increasing overall quality of life. Several indirect methods have been used to measure adherence including the Simplified Medication Adherence Questionnaire (SMAQ). Objective: The objective of this study is to evaluate the reliability and validity of the SMAQ in men living with HIV/AIDS attending a Mexican national hospital. Methods: A cross-sectional analytical design study was carried out in a Mexican National Hospital in Jalisco, including men aged >18 years with at least 3 months of antiretroviral treatment, excluding those with cognitive difficulties in answering the survey. A minimum sample size was calculated to detect the contribution of the variables within the model. The analysis included descriptive tests, confirmatory factor analysis, reliability and validity assessment, correlation between adherence and viral load, and association between viral load and adherence. Results: The final analysis included a total of 260 patients with a mean age of 43 (SD 12) years and an average of 8.97 (SD 6.33) years on antiretroviral treatment. The SMAQ showed sufficient structural validity (comparative fit index=1, root-mean-square error of approximation=0, 90% CI 0-0.085) with satisfactory factor loadings on most questions except item 2 (Do you always take your medication at the prescribed time?). The reliability of the scale is acceptable (Cronbach α=0.702, ω=0.718). Adherence correlated with viral load significantly but not with recent TCD4 lymphocyte levels. Patients classified as adherent were three times more likely to be undetectable than nonadherent patients (odds ratio 3.31, 95% CI 1.13-9.64, P=.04). Conclusions: The SMAQ represents an adequate tool to assess adherence in men living with HIV in the Mexican context, this will contribute to this study and compression of adherence to establish future intervention programs.
- 7 January 2025
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 14 (1) , e59562
Open AccessSimplified Medication Adherence Questionnaire (SMAQ) for People Living With HIV in a National Hospital in Mexico: Instrument Validation Study
Background: Adherence to antiretroviral therapy is a critical component in achieving viral suppression in people living with HIV in addition to increasing overall quality of life. Several indirect methods have been used to measure adherence including the Simplified Medication Adherence Questionnaire (SMAQ). Objective: The objective of this study is to evaluate the reliability and validity of the SMAQ in men living with HIV/AIDS attending a Mexican national hospital. Methods: A cross-sectional analytical design study was carried out in a Mexican National Hospital in Jalisco, including men aged >18 years with at least 3 months of antiretroviral treatment, excluding those with cognitive difficulties in answering the survey. A minimum sample size was calculated to detect the contribution of the variables within the model. The analysis included descriptive tests, confirmatory factor analysis, reliability and validity assessment, correlation between adherence and viral load, and association between viral load and adherence. Results: The final analysis included a total of 260 patients with a mean age of 43 (SD 12) years and an average of 8.97 (SD 6.33) years on antiretroviral treatment. The SMAQ showed sufficient structural validity (comparative fit index=1, root-mean-square error of approximation=0, 90% CI 0-0.085) with satisfactory factor loadings on most questions except item 2 (Do you always take your medication at the prescribed time?). The reliability of the scale is acceptable (Cronbach α=0.702, ω=0.718). Adherence correlated with viral load significantly but not with recent TCD4 lymphocyte levels. Patients classified as adherent were three times more likely to be undetectable than nonadherent patients (odds ratio 3.31, 95% CI 1.13-9.64, P=.04). Conclusions: The SMAQ represents an adequate tool to assess adherence in men living with HIV in the Mexican context, this will contribute to this study and compression of adherence to establish future intervention programs.
- Open Access
- 15 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Simplified Medication Adherence Questionnaire (SMAQ) for People Living With HIV in a National Hospital in Mexico: Instrument Validation Study (Preprint)
BACKGROUND Adherence to antiretroviral therapy is a critical component in achieving viral suppression in people living with HIV in addition to increasing overall quality of life. Several indirect methods have been used to measure adherence including the Simplified Medication Adherence Questionnaire (SMAQ). OBJECTIVE The objective of this study is to evaluate the reliability and validity of the SMAQ in men living with HIV/AIDS attending a Mexican national hospital. METHODS A cross-sectional analytical design study was carried out in a Mexican National Hospital in Jalisco, including men aged >18 years with at least 3 months of antiretroviral treatment, excluding those with cognitive difficulties in answering the survey. A minimum sample size was calculated to detect the contribution of the variables within the model. The analysis included descriptive tests, confirmatory factor analysis, reliability and validity assessment, correlation between adherence and viral load, and association between viral load and adherence. RESULTS The final analysis included a total of 260 patients with a mean age of 43 (SD 12) years and an average of 8.97 (SD 6.33) years on antiretroviral treatment. The SMAQ showed sufficient structural validity (comparative fit index=1, root-mean-square error of approximation=0, 90% CI 0-0.085) with satisfactory factor loadings on most questions except item 2 (Do you always take your medication at the prescribed time?). The reliability of the scale is acceptable (Cronbach α=0.702, ω=0.718). Adherence correlated with viral load significantly but not with recent TCD4 lymphocyte levels. Patients classified as adherent were three times more likely to be undetectable than nonadherent patients (odds ratio 3.31, 95% CI 1.13-9.64, P=.04). CONCLUSIONS The SMAQ represents an adequate tool to assess adherence in men living with HIV in the Mexican context, this will contribute to this study and compression of adherence to establish future intervention programs.
- 15 April 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessSimplified Medication Adherence Questionnaire (SMAQ) for People Living With HIV in a National Hospital in Mexico: Instrument Validation Study (Preprint)
BACKGROUND Adherence to antiretroviral therapy is a critical component in achieving viral suppression in people living with HIV in addition to increasing overall quality of life. Several indirect methods have been used to measure adherence including the Simplified Medication Adherence Questionnaire (SMAQ). OBJECTIVE The objective of this study is to evaluate the reliability and validity of the SMAQ in men living with HIV/AIDS attending a Mexican national hospital. METHODS A cross-sectional analytical design study was carried out in a Mexican National Hospital in Jalisco, including men aged >18 years with at least 3 months of antiretroviral treatment, excluding those with cognitive difficulties in answering the survey. A minimum sample size was calculated to detect the contribution of the variables within the model. The analysis included descriptive tests, confirmatory factor analysis, reliability and validity assessment, correlation between adherence and viral load, and association between viral load and adherence. RESULTS The final analysis included a total of 260 patients with a mean age of 43 (SD 12) years and an average of 8.97 (SD 6.33) years on antiretroviral treatment. The SMAQ showed sufficient structural validity (comparative fit index=1, root-mean-square error of approximation=0, 90% CI 0-0.085) with satisfactory factor loadings on most questions except item 2 (Do you always take your medication at the prescribed time?). The reliability of the scale is acceptable (Cronbach α=0.702, ω=0.718). Adherence correlated with viral load significantly but not with recent TCD4 lymphocyte levels. Patients classified as adherent were three times more likely to be undetectable than nonadherent patients (odds ratio 3.31, 95% CI 1.13-9.64, P=.04). CONCLUSIONS The SMAQ represents an adequate tool to assess adherence in men living with HIV in the Mexican context, this will contribute to this study and compression of adherence to establish future intervention programs.
- 23 August 2023
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 34 (14) , 1042-1052
Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection
Background: Antiretroviral therapy has increased the life expectancy of people living with HIV. However, this increase is not free of comorbidities, and metabolic syndrome is one of the most prevalent. Berberine is an alkaloid nutraceutical that has been shown to ameliorate metabolic disorders such as prediabetes, polycystic ovary syndrome, and non-alcoholic fatty liver disease. However, it has not been tested in HIV infection. Therefore, we conducted a randomized controlled trial to evaluate the efficacy of berberine in improving metabolic syndrome. Methods and results: In this double-blind, placebo-controlled trial, adults living with HIV under virological suppression and metabolic syndrome received either berberine 500 mg TID or placebo for 20 weeks. The primary outcomes were a composite of weight reduction, insulin resistance decrease, and lipid profile improvement. A total of 43 participants were randomized (22 in the berberine group and 21 in the placebo group); 36 participants completed the follow-up and were analyzed. The berberine group showed a reduction in weight and body mass index, lower insulin resistance, and a reduction in TNF-alpha. The control group had higher total cholesterol, c-LDL, and IL-6 concentration. Conclusion: In people living with HIV under virological suppression, berberine was safe and improves clinical and biochemical components of metabolic syndrome. However, further studies with more participants and longer intervention periods need to be explored.
- 23 August 2023
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 34 (14) , 1042-1052
Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection
Background: Antiretroviral therapy has increased the life expectancy of people living with HIV. However, this increase is not free of comorbidities, and metabolic syndrome is one of the most prevalent. Berberine is an alkaloid nutraceutical that has been shown to ameliorate metabolic disorders such as prediabetes, polycystic ovary syndrome, and non-alcoholic fatty liver disease. However, it has not been tested in HIV infection. Therefore, we conducted a randomized controlled trial to evaluate the efficacy of berberine in improving metabolic syndrome. Methods and results: In this double-blind, placebo-controlled trial, adults living with HIV under virological suppression and metabolic syndrome received either berberine 500 mg TID or placebo for 20 weeks. The primary outcomes were a composite of weight reduction, insulin resistance decrease, and lipid profile improvement. A total of 43 participants were randomized (22 in the berberine group and 21 in the placebo group); 36 participants completed the follow-up and were analyzed. The berberine group showed a reduction in weight and body mass index, lower insulin resistance, and a reduction in TNF-alpha. The control group had higher total cholesterol, c-LDL, and IL-6 concentration. Conclusion: In people living with HIV under virological suppression, berberine was safe and improves clinical and biochemical components of metabolic syndrome. However, further studies with more participants and longer intervention periods need to be explored.